Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* history of asthma for ≥ 6 months~* taking inhaled corticosteroids~* non-smoking~* Baseline (pre-bronchodilator) FEV1 35-80% predicted at screening.~* Reversible airways disease as indicated by an increase of FEV1 ≥12% from baseline after nebulised salbutamol or albuterol.~* symptomatic according to the ACQ-7~Exclusion Criteria:~* Unstable severe asthma~* Recent respiratory illness~* Presence of other respiratory disease or chronic pulmonary condition other than asthma~* Treatment with omalizumab within 4 months of study~* Recent gastrointestinal or respiratory parasitic infestation~* History of severe allergy to food or drugs~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GSK679586 (Type: EXPERIMENTAL): Subjects will receive three, once monthly intravenous administration of 10 mg/kg of GSK679586, according to randomization
- PLACEBO (Type: PLACEBO_COMPARATOR): Subjects will receive three, once monthly intravenous administration of saline, according to randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).